Advertisement
New Zealand markets closed
  • NZX 50

    11,717.43
    -117.59 (-0.99%)
     
  • NZD/USD

    0.6086
    +0.0002 (+0.04%)
     
  • NZD/EUR

    0.5680
    +0.0002 (+0.04%)
     
  • ALL ORDS

    8,044.30
    +41.50 (+0.52%)
     
  • ASX 200

    7,801.70
    +42.10 (+0.54%)
     
  • OIL

    81.96
    +0.22 (+0.27%)
     
  • GOLD

    2,335.90
    -0.70 (-0.03%)
     
  • NASDAQ

    19,789.03
    +37.98 (+0.19%)
     
  • FTSE

    8,179.68
    -45.65 (-0.55%)
     
  • Dow Jones

    39,164.06
    +36.26 (+0.09%)
     
  • DAX

    18,210.55
    +55.31 (+0.30%)
     
  • Hang Seng

    17,716.47
    -373.46 (-2.06%)
     
  • NIKKEI 225

    39,569.90
    +228.36 (+0.58%)
     
  • NZD/JPY

    97.7450
    +0.0120 (+0.01%)
     

Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways

Altimmune, Inc
Altimmune, Inc

GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 2nd Annual Virtual Obesity Investor Day, being held on June 26, 2024, to discuss key takeaways from the American Diabetes Association’s (ADA) Scientific Sessions. Details on the fireside chat are as follows:

Title:

Piper Sandler Virtual Obesity Investor Day

 

 

Presenters:

Vipin Garg, Ph.D., Chief Executive Officer
Scott Roberts, Ph.D., Chief Scientific Officer

 

 

Date/Time:

Wednesday, June 26, 2024 at 9:30 a.m. EDT

 

The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

ADVERTISEMENT

About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com

Investor Contacts:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com

Media Contact:
Danielle Cantey
Inizio Evoke Comms
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com